Patent claims covering Ixogen’s core technology have been granted in the UK, the US and Japan and are expected to be granted in Europe shortly.

These patents will provide protection in the UK, US, Japan and Europe for the use of the Ixovex-1 virus as an anti-cancer agent up until November 2033, with the possibility of a further 5 years’ protection in Europe beyond that. Moreover, the positive outcome from examination in the UK, US, Japan and Europe suggests that equivalent patent protection of similar breadth should be allowable in the other major commercial territories of the world.